A new injectable drug called retatrutide, often referred to as 'triple-G,' is showing significant promise in the treatment of Type 2 diabetes and obesity. The drug was the subject of a report on April 1, 2026.

How Retatrutide Works

Retatrutide uniquely impacts three hormones – GLP-1, GIP, and glucagon – while most existing medications only target one or two. This triple action is designed to provide a more comprehensive effect on blood sugar control and weight management.

Clinical Trial Results

Clinical trials revealed that retatrutide reduced blood sugar HbA1C levels by 1.9%, comparable to the efficacy of Eli Lilly’s existing drug, Mounjaro. However, retatrutide also triggered an average of 15% total weight loss within the first 40 weeks of treatment.

Addressing Challenges in Type 2 Diabetes

Researchers noted that achieving both A1C control and weight loss can be difficult for individuals with Type 2 diabetes, as obesity is historically harder to treat in this population. Retatrutide aims to address this challenge with its combined hormonal impact.

Potential Concerns and Side Effects

Some trial participants discontinued retatrutide or lowered their dosage due to concerns about rapid weight loss. Patients reported losing 20-30% of their body weight within a year, and at least one participant developed a kidney stone, though a direct link wasn't established.

Expert Warnings

Health experts caution that the pursuit of drugs with the highest weight loss potential may prioritize stock market value over patient health. Dr. James Batsis, an associate professor at the University of North Carolina School of Medicine, expressed concern that current weight loss drugs might already be too potent for some patients.

One of Dr. Batsis’s elderly patients experienced significant weight loss, leading to frailty and a hip fracture after a fall. While substantial weight loss can benefit severely obese patients, losing that much weight could be detrimental to the health of most individuals eligible for these drugs.

Future Availability

Eli Lilly anticipates retatrutide will join its portfolio of diabetes and obesity medications, including Mounjaro and Zepbound, with an estimated approval date sometime in 2027. Dr. Sean Wight stated, “With triple agonist retatrutide, we set out to make a molecule that could help patients achieve substantial A1C reduction and weight loss.” He added, “These results support the remarkable potential of this novel molecule for people living with T2D, with up to 2% A1C improvement and a nearly 17% weight loss in 40 weeks of treatment.”